A$539,000 RPM revenue and A$3.499 million operating cash outflow

Record RPM revenue meets severe liquidity pressure

Adherium Limited (ASX:ADR) extended its commercial run in the September quarter, recording A$539,000 of recurring remote patient monitoring subscription revenue, up 12.5% from the June quarter and marking the fifth consecutive quarterly record. The more immediate investor issue, however, was the balance sheet: cash fell to A$120,000 at 30 September after operating activities consumed A$3.499 million.

Customer cash receipts rose 33% quarter-on-quarter to A$544,000, helped by the expanding Hailie platform. The figure remains well below quarterly operating payments, which included A$2.087 million for staff and contractors, A$1.472 million for administration and corporate costs, and A$376,000 for research and development. The Appendix 4C calculates just 0.03 quarters of funding from quarter-end cash and reported no unused financing facilities.

Device activations build the recurring revenue base

Adherium added 1,033 device shipments and 900 activations during the quarter, taking cumulative totals to 6,392 and 4,732 respectively. The company says shipments lead revenue, with billable subscription revenue recognised as patients are activated. It also reported that cumulative shipments rose from 765 a year earlier, while activations increased 66% on a compound quarterly growth-rate basis over the same period.

“RPM Revenue Growth”

The result builds on the fourth record RPM quarter, when recurring subscription revenue reached A$479,000 and the company highlighted the potential to move from fee-for-service monitoring into larger US value-based care arrangements. In the latest quarter, Adherium said it was using retention analytics, patient-risk segmentation and additional clinical support during the first seven days of onboarding to improve the quality and durability of patient growth.

Post-quarter funding buys time, not financial independence

Adherium received a A$700,000 Barvest Ventures loan on 7 October, a A$257,917 milestone payment from AstraZeneca Pharmaceuticals on 9 October, and a further A$750,000 Barvest facility on 30 October. Those receipts came after the quarter-end cash calculation and therefore do not alter the 0.03-quarter funding figure reported in the 4C, but they provide additional liquidity after the reporting date.

The company’s existing Trudell loan facility stood at A$4.671 million at quarter end, with A$82,501 of accrued interest. The facility combines earlier short-term borrowings into a term loan due on 31 August 2027. Adherium said it expects to raise sufficient funds to support operations, while the scale and timing of any further funding remain unresolved in the filing.

Value-based care expansion faces reimbursement and execution tests

Adherium is positioning its patient data, clinical team and Hailie sensor infrastructure for value-based care contracts with US insurers, health systems and accountable care organisations. It also expanded its US commercial footprint during and after the quarter, including a partnership with Florida Lung, Asthma & Sleep Specialists in Central Florida and further participation across Allergy Partners’ clinic network.

The strategy carries several dependencies. CMS is due to finalise its proposed CY2027 physician fee schedule in November, with potential changes to RPM and remote therapeutic monitoring eligibility, payment rates and service requirements. Adherium is assessing the proposal’s effect on its current delivery model. The company is also continuing a 20-person feasibility study at Lurie Children’s Hospital and further analysis of the Intermountain Health iCARE dataset, with clinical evidence described as preliminary and still under evaluation.